{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:52:28Z","timestamp":1790610748932,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","award":["Z191100006619088"],"award-info":[{"award-number":["Z191100006619088"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clineuro.2024.108579","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:03:57Z","timestamp":1727827437000},"page":"108579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of IDH-mutated gliomas"],"prefix":"10.1016","volume":"246","author":[{"given":"Yuying","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clineuro.2024.108579_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2014.1205","article-title":"IDH mutation in glioma: new insights and promises for the future","volume":"71","author":"Turkalp","year":"2014","journal-title":"JAMA Neurol."},{"issue":"23","key":"10.1016\/j.clineuro.2024.108579_bib2","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1002\/cncr.31039","article-title":"Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications","volume":"123","author":"Miller","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clineuro.2024.108579_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2024.108579_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/srep44792","article-title":"Metabolic Profiling of IDH mutation and malignant progression in infiltrating glioma","volume":"7","author":"Jalbert","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108579_bib5","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/jmri.26964","article-title":"Identification of IDH and TERTp mutation status using (1) H-MRS in 112 hemispheric diffuse gliomas","volume":"51","author":"Ozturk-Isik","year":"2020","journal-title":"J. Magn. Reson. Imaging"},{"issue":"6","key":"10.1016\/j.clineuro.2024.108579_bib6","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1007\/s00330-021-08522-4","article-title":"Mean apparent propagator-MRI in evaluation of glioma grade, cellular proliferation, and IDH-1 gene mutation status","volume":"32","author":"Sun","year":"2022","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108579_bib7","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.210820","article-title":"Whole-tumor histogram analysis of multiple diffusion metrics for glioma genotyping","volume":"302","author":"Gao","year":"2022","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.clineuro.2024.108579_bib8","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1007\/s00330-020-06702-2","article-title":"Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas","volume":"30","author":"Wu","year":"2020","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.clineuro.2024.108579_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2020.102427","article-title":"Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients","volume":"28","author":"Regnery","year":"2020","journal-title":"Neuroimage. Clin."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1148\/radiol.2019191140","article-title":"MRI and CT Identify Isocitrate Dehydrogenase (IDH)-mutant lower-grade gliomas misclassified to 1p\/19q codeletion status with fluorescence in situ hybridization","volume":"294","author":"Patel","year":"2020","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.clineuro.2024.108579_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/neuonc\/noz199","article-title":"A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas","volume":"22","author":"Bangalore Yogananda","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108579_bib12","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1007\/s00330-019-06548-3","article-title":"Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma","volume":"30","author":"Kim","year":"2020","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib13","article-title":"Predictive accuracy of T2-FLAIR mismatch sign for the IDH-mutant, 1p\/19q noncodeleted low-grade glioma: An updated systematic review and meta-analysis","volume":"4","author":"Do","year":"2022","journal-title":"Neurooncol. Adv."},{"issue":"11","key":"10.1016\/j.clineuro.2024.108579_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010324","article-title":"T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: variability and evolution","volume":"95","author":"Throckmorton","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clineuro.2024.108579_bib15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/neuonc\/noy048","article-title":"The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower-grade glioma: a validation study","volume":"20","author":"Broen","year":"2018","journal-title":"Neuro. Oncol."},{"issue":"7","key":"10.1016\/j.clineuro.2024.108579_bib16","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1007\/s00330-020-07467-4","article-title":"The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p\/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis","volume":"31","author":"Park","year":"2021","journal-title":"Eur. Radiol."},{"issue":"1129","key":"10.1016\/j.clineuro.2024.108579_bib17","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210825","article-title":"T2-FLAIR mismatch sign: a roadmap of pearls and pitfalls","volume":"95","author":"Pinto","year":"2022","journal-title":"Br. J. Radiol."},{"issue":"9","key":"10.1016\/j.clineuro.2024.108579_bib18","article-title":"The T2-FLAIR Mismatch Sign as an Imaging Indicator of IDH-Mutant, 1p\/19q non-codeleted lower grade gliomas: a systematic review and diagnostic accuracy meta-analysis","volume":"11","author":"Adamou","year":"2021","journal-title":"Diagn. (Basel)"},{"issue":"8","key":"10.1016\/j.clineuro.2024.108579_bib19","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro. Oncol."},{"issue":"20","key":"10.1016\/j.clineuro.2024.108579_bib20","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-17-0560","article-title":"T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p\/19q Status in Lower-grade Gliomas: a TCGA\/TCIA Project","volume":"23","author":"Patel","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.clineuro.2024.108579_bib21","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00701-021-04914-z","article-title":"Brain infarctions after glioma surgery: prevalence, radiological characteristics and risk factors","volume":"163","author":"Strand","year":"2021","journal-title":"Acta Neurochir. (Wien. )"},{"issue":"65","key":"10.1016\/j.clineuro.2024.108579_bib22","doi-asserted-by":"crossref","first-page":"109175","DOI":"10.18632\/oncotarget.22646","article-title":"Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.clineuro.2024.108579_bib23","first-page":"4109","article-title":"p16INK4a and Ki-67 measurement predict progression of cervical low-grade squamous intraepithelial lesion","volume":"11","author":"Zhang","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.20892\/j.issn.2095-3941.2020.0179","article-title":"Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma","volume":"18","author":"Chai","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-018-0143-2","article-title":"A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas","volume":"32","author":"Chai","year":"2019","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40478-020-00913-w","article-title":"The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation","volume":"8","author":"Chai","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53629-w","article-title":"Intratumoral susceptibility signals reflect biomarker status in gliomas","volume":"9","author":"Kong","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clineuro.2024.108579_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.108924","article-title":"T2-FLAIR mismatch sign in dysembryoplasticneuroepithelial tumor","volume":"126","author":"Onishi","year":"2020","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108579_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11060-018-03034-6","article-title":"Radiographic assessment of contrast enhancement and T2\/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups","volume":"141","author":"Juratli","year":"2019","journal-title":"J. Neurooncol."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108579_bib30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00330-019-06395-2","article-title":"Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2\/FLAIR mismatch sign","volume":"30","author":"Lee","year":"2020","journal-title":"Eur. Radiol."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108579_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041037","article-title":"Multi-Parametric Radiomic Model to Predict 1p\/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign","volume":"15","author":"Kihira","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clineuro.2024.108579_bib32","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/neuonc\/noy048","article-title":"The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower-grade glioma: a validation study","volume":"20","author":"Broen","year":"2018","journal-title":"Neuro. Oncol."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108579_bib33","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1007\/s00330-021-08500-w","article-title":"Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p\/19q non-codeleted lower-grade glioma","volume":"32","author":"Li","year":"2022","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108579_bib34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-021-03720-y","article-title":"Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma","volume":"152","author":"Patel","year":"2021","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.clineuro.2024.108579_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106745","article-title":"Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma","volume":"207","author":"\u00c7elik","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.clineuro.2024.108579_bib36","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.wneu.2021.02.042","article-title":"The histopathologic and radiologic features of T2-FLAIR mismatch sign in IDH-mutant 1p\/19q Non-codeleted Astrocytomas","volume":"149","author":"Fujita","year":"2021","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib37","article-title":"T2\/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p\/19q non-codeleted gliomas: validity and pathophysiology","volume":"2","author":"Foltyn","year":"2020","journal-title":"Neurooncol. Adv."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108579_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-020-03611-8","article-title":"Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign","volume":"149","author":"Aliotta","year":"2020","journal-title":"J. Neurooncol."},{"issue":"12","key":"10.1016\/j.clineuro.2024.108579_bib39","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1177\/0284185120973624","article-title":"Predicting 1p\/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas","volume":"62","author":"Yang","year":"2021","journal-title":"Acta Radiol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108579_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67244-7","article-title":"Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas","volume":"10","author":"Deguchi","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.clineuro.2024.108579_bib41","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00234-023-03196-9","article-title":"Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium","volume":"65","author":"Lee","year":"2023","journal-title":"Neuroradiology"},{"issue":"8","key":"10.1016\/j.clineuro.2024.108579_bib42","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1016\/j.acra.2024.02.009","article-title":"Machine-learning and radiomics-based preoperative prediction of Ki-67 expression in glioma using MRI data","volume":"31","author":"Ni","year":"2024","journal-title":"Acad. Radiol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724004669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724004669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T17:47:00Z","timestamp":1731520020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724004669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"alternative-id":["S0303846724004669"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108579","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of IDH-mutated gliomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108579"}}